• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Castle Biosciences, Inc. - Common stock (NQ:CSTL)

    41.49 -0.66 (-1.55%)
    Streaming Delayed Price Updated: 12:28 PM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 101,185
    Open 41.94
    Bid (Size) 41.37 (200)
    Ask (Size) 41.55 (400)
    Prev. Close 42.15
    Today's Range 41.10 - 42.31
    52wk Range 14.59 - 43.01
    Shares Outstanding 25,167,365
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
    Via Chartmill
    News headline image
    CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
    Via AB Newswire
    Topics Intellectual Property

    Performance

    YTD
    +7.7%
    +7.7%
    1 Month
    +3.2%
    +3.2%
    3 Month
    +71.6%
    +71.6%
    6 Month
    +152.6%
    +152.6%
    1 Year
    +55.9%
    +55.9%

    More News

    Read More
    News headline image
    Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    News headline image
    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Why Castle Biosciences' Rally Might Just Be Getting Started ↗
    Via Benzinga
    News headline image
    AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
    Via Benzinga
    News headline image
    Castle Biosciences Reports Third Quarter 2025 Results
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    A Glimpse of Castle Biosciences's Earnings Potential ↗
    Via Benzinga
    News headline image
    Castle Biosciences to Participate in Upcoming Investor Conferences
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
    From Castle Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Castle Biosciences, Inc. - Common stock publicly traded?
    Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
    What exchange does Castle Biosciences, Inc. - Common stock trade on?
    Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
    The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
    What is the current price of Castle Biosciences, Inc. - Common stock?
    The current price of Castle Biosciences, Inc. - Common stock is 41.49
    When was Castle Biosciences, Inc. - Common stock last traded?
    The last trade of Castle Biosciences, Inc. - Common stock was at 01/23/26 12:28 PM ET
    What is the market capitalization of Castle Biosciences, Inc. - Common stock?
    The market capitalization of Castle Biosciences, Inc. - Common stock is 1.04B
    How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
    Castle Biosciences, Inc. - Common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.